$Stock*Shop*Charts*News*Option$

[morcash]

(nasd) SQNM Sequenom Abstract Selected for ''Blue Ribbon'' Designation for Presentation at ACOG Annual Meeting
Wednesday, May 07 2008 - 4:00

$0.0 $0.0 (%0.0)

SAN DIEGO--(BUSINESS WIRE)--

Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic analysis solutions, today announced that a study indicating that noninvasive prenatal genetic testing using maternal plasma may be routinely used to characterize fetal Rhesus D (RHD) genotypes was presented in a poster session at the American College of Obstetricians and Gynecologists (ACOG) 56th Annual Clinical Meeting being held in New Orleans. The "blue ribbon" designation is reserved for those abstracts receiving the highest ranking by ACOG.

The study also concluded that a prototype test using the SEQureDx(TM) Technology developed to run on Sequenom's MassARRAY(R) system further demonstrated the universal potential for noninvasive prenatal testing. The poster, "A Novel Cell Free Fetal (ccff) DNA Test for RHD Shows 100% Accuracy in Non-invasive Prenatal Testing," was authored by Yanfeng Yang, Min Lee, Huining Liang and Brandy Klotzle, all from Sequenom; Tobias Legler Department of Transfusion Medicine, University of Gottingen, Germany; and Kenneth J. Moise, Baylor College of Medicine in Houston.

"We are truly excited that ACOG awarded this study with its blue ribbon designation," said Betty Dragon, Ph.D., Senior Vice President of Research & Development, Sequenom. "While similar studies have supported the introduction of noninvasive RHD genotyping of fetuses from RhD-negative mothers, the majority of reported studies have been conducted on the Real Time-PCR platform, which requires multiple repeat reactions to detect all targets for each patient sample. This study demonstrated 100% accuracy using a convenient single-reaction test for RHD genotyping. We look forward to the commercial launch of a Laboratory Developed Test method using the SEQureDx Technology for RHD fetal genotyping on the MassARRAY platform through our partner labs in mid-2008."



About Sequenom

Sequenom is committed to providing the best genetic analysis products that translate genomic science into superior solutions for biomedical research, livestock and agricultural applications, molecular medicine, and noninvasive prenatal testing. Sequenom's proprietary MassARRAY system is a high-performance nucleic acid analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts. Sequenom has exclusively licensed intellectual property rights for the development and commercialization of noninvasive prenatal genetic tests for use with the MassARRAY system and other platforms.

Sequenom(R), MassARRAY(R) and SEQureDx(TM) are trademarks of Sequenom, Inc.

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the potential for noninvasive prenatal testing and Sequenom's intentions to launch a Laboratory Developed Test method for RHD fetal genotyping in mid-2008, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with demand for and market acceptance of Sequenom's products, services, and technologies, new technology and product development and commercialization, reliance upon the collaborative efforts of other parties, research and development progress, competition, government regulation, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and subsequent periodic reports. These forward-looking statements are based on current information that is likely to change and speak only as of the date hereof. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Source: Sequenom, Inc.